Phalgoon Shah, MD
Pulmonary Disease · Edgewood, KYNPI 1821409319
Payments from drug & device makers
Across 194 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$977
- AstraZeneca$598
- Boehringer Ingelheim$301
- Mylan Specialty L.p.$170
- Actelion Pharmaceuticals US, Inc.$150
- Insmed, Inc.$149
- plus $2K from 27 others
What the payments were for
- Travel & lodging$251%
- Food & beverage$3,94799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 67 | $977 |
| AstraZeneca | 23 | $598 |
| Boehringer Ingelheim | 20 | $301 |
| Mylan Specialty L.p. | 9 | $170 |
| Actelion Pharmaceuticals US, Inc. | 8 | $150 |
| Insmed, Inc. | 2 | $149 |
| Mallinckrodt Hospital Products Inc. | 6 | $139 |
| Amgen | 2 | $133 |
| Regeneron Healthcare Solutions, Inc. | 7 | $131 |
| La Jolla Pharmaceutical Company | 2 | $128 |
| Genentech USA, Inc. | 2 | $128 |
| Mallinckrodt Enterprises LLC | 1 | $118 |
| Grifols USA, LLC | 6 | $102 |
| Sanofi | 5 | $90 |
| Body Vision Medical Inc. | 1 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| AbbVie(2 entities) | 4 | $60 |
| Jazz Pharmaceuticals Inc. | 3 | $51 |
| Verona Pharma, Inc. | 2 | $49 |
| Gilead | 3 | $37 |
| Pulmonx Corporation | 2 | $35 |
| Novartis | 2 | $32 |
| United Therapeutics Corporation | 1 | $32 |
| Merck | 2 | $30 |
| Baxter Healthcare | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| Intuitive Surgical | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,972 in reported general payments places this provider in the 45th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 188 | $152,808 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $44,297 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 65 | $42,684 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $18,031 |
| Spiriva HandihalerTiotropium Bromide | 17 | $12,885 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,337 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $10,020 |
| Spiriva RespimatTiotropium Bromide | 13 | $9,826 |
| DuleraMometasone/Formoterol | 14 | $5,979 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $3,907 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $3,290 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,677 |
| Montelukast Sodium | 215 | $1,477 |
| Roflumilast | 19 | $617 |
| Fluticasone Propionate | 41 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $977 | $207,442293 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $301 | $52,51078 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $598 | $28,05156 claims |
| MerckDulera | $30 | $5,97914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Edgewood
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Steven KoenigMorehead$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.